Financial Gravity Asset Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-22
Closed -$102 2092
2024
Q1
$102 Buy
22
+16
+267% +$74 ﹤0.01% 1736
2023
Q4
$38 Buy
6
+3
+100% +$18 ﹤0.01% 1364
2023
Q3
$22 Sell
3
-4
-57% -$32 ﹤0.01% 1126
2023
Q2
$64 Hold
7
﹤0.01% 1369
2023
Q1
$4 Sell
7
-3
-30% -$28 ﹤0.01% 940
2022
Q4
$12 Sell
10
-98
-91% -$1.73K ﹤0.01% 1356
2022
Q3
$11 Sell
108
-198
-65% -$8.58K ﹤0.01% 755
2022
Q2
$31 Sell
306
-138
-31% -$7.15K ﹤0.01% 633
2022
Q1
$45 Sell
444
-414
-48% -$36.9K ﹤0.01% 652
2021
Q4
$88 Buy
858
+857
+85,700% +$147K ﹤0.01% 680
2021
Q3
$207K Hold
1
0.1% 171
2021
Q2
$212K Hold
1
0.08% 176
2021
Q1
$237 Sell
1
-1
-50% -$199 ﹤0.01% 440
2020
Q4
$0 Buy
+2
New +$213 ﹤0.01% 619

Other funds holding NVAX

Financial Gravity Asset Management's NVAX Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Novavax (NVAX) in Q2 2024, closing a stake of 22 shares — an estimated $102 sold.

Financial Gravity Asset Management first reported a position in NVAX in Q4 2020 and held it in 14 quarters. The position peaked at $212K in Q2 2021. 229 funds tracked by Wall St. Rank hold NVAX as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Novavax position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 22 Novavax shares in Q2 2024, an estimated $102.
  • Financial Gravity Asset Management first reported a position in Novavax in Q4 2020 and held it in 14 quarters.
  • Financial Gravity Asset Management's Novavax position peaked at $212K in Q2 2021.
  • 229 funds tracked by Wall St. Rank held Novavax as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.